Acrivon Therapeutics, Inc. · NASDAQ:ACRV
Acrivon Therapeutics — Corporate Update (January 2026)
31 slides from Acrivon Therapeutics's corporate update, Jan 8, 2026
Slide 1: ACR-368 and ACR-2316 Clinical Data and AP3 Pipeline Updates
ACR-368 AND ACR-2316 CLINICAL DATA AND AP3 PIPELINE UPDATES ACRIVON CONFERENCE CALL January 8, 2026
Slide 2: Forward-looking statements
Forward-looking statements Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of operations or financial condition, business strategy and plans and objectives o
Slide 3: Acrivon Team Participants
Peter Blume-Jensen M.D., Ph.D. CEO, President, and Co-Founder Inventor of the AP3 Platform Acrivon TEAM Participants Adam Levy Ph.D., M.B.A. Chief Financial Officer Mansoor Raza Mirza M.D. Chief Medical Officer
Slide 4: Agenda
agenda Introduction and Review of the Agenda (Adam Levy) Brief Overview of Acrivon and Generative Phosphoproteomics: Transforming Drug Discovery with Proteome-Wide SAR (Peter Blume-Jensen) ACR-368 Phase 2b Clinical Data and Program Updates (Mansoor Raza Mirza) ACR-2316 Phase 1 Initial Clinical Data
Slide 5: Acrivon Therapeutics – a next-generation precision medicine company
Acrivon Therapeutics – a next-generation precision medicine company Neurological Cancer Inflammatory Fibrosis Drug P Metabolic Acrivon Predictive Precision Proteomics (AP3) Acrivon’s Generative AI-driven platform Enables an exact match between the disease-driving, dysregulated pathways with a drug’s
Slide 6: Acrivon Pipeline
Acrivon Pipeline Anticipated Next Milestone Phase 3 Phase 2 Phase 1 Preclinical ACR-368 (CHK1/CHK2) Single-Arm Trials Based on OncoSignature Prediction Other Trials Ongoing/Under Consideration: HPV+ SCC (H&N*, Anal, Cervical), Sarcomas, MDS/MPN Clinical Data & Dose Expansion Start, 1H 2026 Clinical
Slide 7: Endometrial cancer predicted to be sensitive to ACR-368 through AP3 indication finding
Endometrial cancer predicted to be sensitive to ACR-368 through ap3 indication finding ACR-368 OncoSignature-based indication finding prior to trial entry ACR-368 OncoSignature imaging demonstrates addiction to CHK1/2 DDR axis Confirmation of predicted sensitivity in genetically non-modified PDX mod
Slide 8: ACR-368: a potent selective CHK1/2 inhibitor
ACR-368: a potent selective CHK1/2 inhibitor ATP-competitive inhibitor of CHK1 (0.9 nM) and CHK2 (8 nM) Exclusively in-licensed from Eli Lilly & Company; originally discovered by Array (Pfizer) Balanced inhibition of CHK1 and CHK2 believed important for RECIST monotherapy activity CoM patent exp. Oc
Slide 9: ACR-368-201 (GOG-3082) trial
ACR-368-201(GOG-3082) trial A Phase 2 Study of ACR-368 Therapy in Subjects with Endometrial Cancer Subjects with endometrial cancer who have relapsed after prior platinum-based chemotherapy and one prior line of anti-PD-(L)1 therapy BM: OncoSignature Biomarker BM-Stratified Cohorts (Prospective Trea
Slide 10: Best overall response in OncoSignature-positive endometrial cancer subjects
* ORR is best of BICR and/or PI # Unconfirmed PR Non QC’ed data based on EDC data extract as of 12/04/2025 with sponsor verification, and if needed correction, of histopathology/molecular alterations, and BOR in last prior line # # ORR* = 39% (ACR-368 single agent) n = 31 Best overall response (BOR)
Slide 11: BOR across all BM+ and BM- subjects
BOR across all BM+ and BM- subjects with ≤ 2 Prior lines n = 25 n = 35 ORR* = 26% (ACR-368 + ULDG combo) ORR* = 44% (ACR-368 single agent) # # # BM+ (≤ 2 Prior Lines) BM- (≤ 2 Prior Lines) * ORR is best of BICR and/or PI # Unconfirmed PR Non QC’ed data based on EDC data extract as of 12/04/2025 with
Slide 12: BoR in BM+ subjects by endometrial cancer subtype
n = 12 Median Prior Lines = 1 n = 5 Median Prior Lines = 1 n = 7 Median Prior Lines = 1 Serous Carcinosarcoma Endometrioid Clear-Cell # # ORR* = 67% BoR in BM+ subjects (arm1) by endometrial cancer subtype and molecular status (≤2 prior lines) ULDG predicted to also sensitize BM+ patients to ACR-368
Slide 13: BOR across serous vs non-serous subjects
# BOR across all serous vs all non-serous subjects (biomarker-unselected) with ≤ 2 Prior lines n = 23 Median Prior Lines = 1 n = 37 Median Prior Lines = 2 Serous (≤ 2 Prior Lines) Non-Serous (≤ 2 Prior Lines) # # ORR* = 22% ORR* = 52% * ORR is best of BICR and/or PI # Unconfirmed PR Non QC’ed data b
Slide 14: Disease control and clinical benefit rate in serous subjects
Arm 2, Serous, ≤ 2 Prior Lines (DCR: 55%, CBR (16 weeks): 45%) Arm 1, Serous, ≤ 2 Prior Lines (DCR: 92%, CBR (16 weeks): 83%) If RECIST Response is the same for BICR and Investigator, BICR is used. Disease control rate (DCR) and clinical benefit rate (CBR) in serous subjects with ≤ 2 prior lines of
Slide 15: Serous endometrial cancer represents a significant unmet need
Serous endometrial cancer represents a significant unmet need Disproportionate Mortality: Accounts for ~40% of all endometrial cancer deaths*. Outcomes have only moderately improved over decades. Limited Effective Targeted Therapies: HER2-targeting benefits only a proportion. No validated targets fo
Slide 16: Large addressable population (US + EU)
Large addressable population (US + EU) Serous endometrial cancer a significant unmet need Annual Endometrial Cancer Patient Mortality (US + EU) = ~44K1, 3 1SEER database 2https://pmc.ncbi.nlm.nih.gov/articles/PMC9445918 3Concin, C. et al, ESGO–ESTRO–ESP 2025 Guidelines; Lian Y., Luo P. Annals of Glo
Slide 17: ACR-368-201 (GOG-3082 and EU) trial
ACR-368-201 (GOG-3082 and EU) trial A Phase 2 Study of ACR-368 Therapy in Subjects with Endometrial Cancer Subjects with endometrial cancer who have relapsed after prior platinum-based chemotherapy and one prior line of anti-PD-(L)1 therapy BM-Stratified Cohorts (Prospective Treatment Response Predi
Slide 18: Synergy of ACR-368 with anti-PD-L1 and immune memory
Potent synergy of ACR-368 with anti-PD-L1 displays immune Memory in 100% of Mice Complete tumor regression Immune memory Immune memory independent of CD8 Immune memory independent of CD4 Immune memory Co-mediated by CD4 + CD8 Legends:
Slide 19: ACR-368 + Anti PD-1 confirmatory Phase 3 trial
ACR-368 + Anti PD-1 confirmatory phase 3 trial Placebo Carboplatin AUC 5 mg/mL/min Paclitaxel 175 mg/m2 Q3W for 6 cycles ACR-368 Q2W plus Anti PD-1 Q6W Placebo plus Anti PD-1 Q6W Follow- up R1:1 Eligible patients Histologically/cytologically proven advanced or recurrent EC Stage III/IV disease or fi
Slide 20: AP3 Generative phosphoproteomics platform
AP3 Generative phosphoproteomics platform Structured Standardized AI-enabled AP3 Interactome AP3 KSR Predictor AP3 Data Portal AP3 Chatbot Proprietary Database Drug design and optimization Target ID / Indication Finding MoA / response prediction PD and predictive biomarkers MS-proteomics Functional
Slide 21: ACR-2316 designed using Acrivon's AP3 platform
Acr-2316 is a potentially best- and first-in-class agent designed using Acrivon’s ap3 platform Program Goals Demonstrated Results Superior single agent activity High selectivity and potency Streamlined clinical development Favorable ADME-PK, Therapeutic Index, and tolerability profile Broad preclini
Slide 22: Phase 1 Dose Escalation and Expansion Design
Phase 1 Dose Escalation and Expansion Design Weekly 3on/4off 2on/5off Dose Level X Dose Level Y Selected Cohort(s) Dose Escalation 30 mg 200 mg 240 mg 120 mg 60 mg 240 mg Bi-weekly 2on/12off 360 mg TBD TBD 160 mg TBD Dose Expansion: Tumor Types TBD ✅ AP3-identified tumors include tumors of high unme
Slide 23: Demographics and Baseline Characteristics
Demographics AND BASELINE CHARACTERISTICS Non QC’ed data based on EDC data extract as of 12/22/2025 Subject Demographics N = 33 ECOG Status at Baseline, n (%) 0 10 (30.3) 1 23(69.7) Prior Lines of Therapy, n (%) 1 1 (3) 2 5 (15.2) 3 14 (42.4) 4 7 (21.2) 5 2 (6) 6 2 (6) 7 1(3) 8 1(3) Prior exposure t
Slide 24: Favorable tolerability profile
Favorable tolerability profile Summary of Grade ≥ 3 TRAEs in >5% of Subjects Subjects with ≥Grade 3 Treatment-Emergent Adverse Events^: # subjects; % 120 mg (N=4) 3 on/4 off 160 mg (N=4) 3 on/4 off 200 mg (N=3) 3 on/4 off 240 mg (N=10) 3 on/4 off 240 mg (N=6) 2 on/5 off Total Gr. 3 N=20* Total Gr. 4
Slide 25: ACR-2316 initial activity in AP3-predicted tumor types
ACR-2316 initial activity in AP3-predicted tumor types A total of 33 patients dosed across two weekly dosing schedules in the ongoing Phase 1 monotherapy dose-escalation study Clinical activity observed at dose level 120 mg and above, with tumor shrinkage in 9 out of 20 evaluable patients, including
Slide 26: ACR-2316 initial clinical activity during dose escalation
ACR-2316 initial clinical activity during dose escalation best tumor shrinkage *Since EDC data extract a subsequent scan showed further shrinkage (69%) of target lesion, but progression of non-target lesions (liver metastases) **Since EDC data extract a subsequent scan has confirmed the PR ^All subj
Slide 27: Potential development paths for ACR-2316
Potential development paths for ACR-2316 AP3-predicted solid tumor types of high unmet need, e.g. SCLC, sqNSCLC, HPV+ tumors, etc. Single agent later line Chemo combination (DDR stress sensitization in earlier lines) Weekly and bi-weekly dosing regimens provide flexibility for combinations, includin
Slide 28: New preclinical development candidate ACR-6840: CDK11 inhibitor
New preclinical cell cycle development candidate ACR-6840: potential first-in-class CDK11 inhibitor No clinical-stage competitors Attractive cancer cell cycle drug target, well-suited for AP3 platform, multiple protein isoforms Broad role in cell cycle control and oncogenesis; CDK11 controls transcr
Slide 29: ACR-6840 is pro-apoptotic and synergizes with BCL2 inhibitors
ACR-6840 is pro-apoptotic, potently downregulates MCL1, and shows synergy with BCL2 inhibitors Rationale: CDK11 inhibition downregulates MCL1 and other BCL2 proteins, resulting in synergy with BCL2 inhibitors Decreases BCL-2 and Bcl-xL mRNA and protein rendering cells more dependent on remaining pro
Slide 30: Financial Highlights
FINANCIAL HIGHLIGHTS Approximate Cash and Investments $119M Projected runway into Q2 2027 Approximate Fully Diluted Shares Outstanding 45.1M Current operating plan, assuming no additional financing Balance sheet 31-Dec-2025 Shares, pre-funded warrants, and equity grants outstanding 31-Dec-2025 Notes
Slide 31: Take home messages
Take home messages ACR-368 ACR-2316 AP3-driven Pipeline SUBTITILE HERE Serous EC shows high proportion of BM+ and high sensitivity to ACR-368 (ORR in BM+ = 67% and ORR in all-comer = 52% in ongoing Ph 2b trial), providing for a highly compelling clinical profile Given expansion to ≥20 EU sites and n
Acrivon Therapeutics — Corporate Update (January 2026) on 6ix